MIV Announces Excellent Safety and Efficacy of VESTAsync(TM) Polymer-Free Drug-Eluting...

MIV Announces Excellent Safety and Efficacy of VESTAsync(TM) Polymer-Free Drug-Eluting Stent at 12-Month Clinical Follow Up

-Completes Nine-Month Follow Up for All Patients in VESTASYNC I
Trial-
ATLANTA--(Business Wire)--
MIV Therapeutics, Inc. (OTCBB: MIVI) (Frankfurt: MIV), a leading
developer of next-generation coatings and advanced drug-delivery
systems for cardiovascular stents and other implantable medical
devices, announced continued excellent safety and efficacy results at
12-month clinical follow up for all 15 patients in its first-in-man
(FIM) VESTASYNC I Trial of its VESTAsync(TM) polymer-free drug-eluting
stent. In addition, data using intravascular ultrasound (IVUS) and
Quantitative Coronary Angiography (QCA) have now been generated for
all 15 patients at nine-month follow up, which showed no difference
from the safety and efficacy data on 11 and 12 patient nine-month data
presented at the American College of Cardiology conference in March.

Dr. Mark Landy, MIV President and Chief Executive Officer
remarked, "We are very excited that the data from the VESTASYNC I FIM
Trial continue to show excellent safety and efficacy, with no major
adverse cardiac events for all 15 patients involved. Significantly, at
this point all of our patients are Plavix-free, and have been so for
at least eight months, which suggests that the VESTAsync(TM)
drug-eluting stent has the potential to reduce the current treatment
paradigm for these patients to short-term anti-coagulant therapy from
the current standard of a minimum of one year."

About MIV Therapeutics

MIV Therapeutics is developing a next-generation line of advanced
biocompatible coatings for passive and drug-eluting applications on
cardiovascular stents, as well as for a broad range of other
implantable medical devices. The Company's ultra-thin coating
formulation is designed to protect surrounding tissue from potentially
harmful interactions with bare metallic stents. This coating platform
is derived from hydroxyapatite (HAp), an organic material that has
demonstrated excellent in vivo safety and biocompatibility.
Hydroxyapatite is a porous material that makes up the bone mineral and
matrix of teeth, and is widely used today as a bone substitute
material and for coatings on implantable fixation devices in
orthopedic, dental and other applications. The Company's novel
polymer-free drug-eluting technologies based on HAp could also provide
an attractive alternative to current polymer-based drug-eluting
coatings on the stent market, which have been associated with
undesirable effects. The Company's drug-eluting coatings are
additionally designed to suit a broad range of implantable medical
devices that could benefit from highly customizable drug release
profiles. MIV Therapeutics has a Collaborative Research Agreement with
the University of British Columbia and has received a government grant
for its research program on the "Development of Novel Drug Eluting
Composite Coatings for Cardiovascular Stents," under the National
Research Council-Industrial Research Assistance Program. Under this
sponsorship, the Company is expected to complete its drug-eluting
research and development program and to reach product
commercialization. MIV's intellectual property portfolio includes
patents held by the University of British Columbia and exclusively
licensed to MIV. Key patent applications filed simultaneously in
various countries around the world further protect the commercial
exclusivity of MIV's inventions in the global marketplace. For more
information, please visit www.mivtherapeutics.com.

Forward-Looking Statements

Except for the historical information contained herein, the
matters discussed in this press release are forward-looking
statements. All statements that discuss expectations and projections
with respect to future matters including, without limitation,
statements relating to the safety and efficacy of the Company's
product and the ability of the Company's product to rejuvenate the
stent market are forward-looking statements. Such statements are
indicated by words or phrases such as "proposed," "expected,"
"believe," "will," "breakthrough," "significant," "indicated," "feel,"
"revolutionary," "should," "ideal," "extremely" and "excited." These
statements are made under "Safe Harbor" provisions of the Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those described in forward-looking statements and are
subject to risks and uncertainties including, without limitation,
market acceptance of the Company's product, the ability of the Company
to raise sufficient funding and to continue to develop its various
business interests as presently contemplated, and other factors
identified in the Company's filings with the Securities and Exchange
Commission including, without limitation, the Company's annual report
on Form 10-K for the year ended May 31, 2007 and Forms 10-Q. The
Company expressly disclaims any obligation to update publicly or
otherwise revise these statements, whether as a result of new
information, future events or otherwise, except to the extent required
by law.

For Investor Inquiries:
MIV Therapeutics, Inc.
Anthony L. Huston
Vice President, Business Development & Investor Relations
604-301-9545, x14
ahuston@mivtherapeutics.com
investor@mivtherapeutics.com
or
Lippert/Heilshorn & Associates, Inc.
Kim Sutton Golodetz, 212-838-3777
kgolodetz@lhai.com
or
For Media Inquiries:
Schwartz Communications
Michele Fox / Cassie Wallace, 781-684-0770
miv@schwartz-pr.com

Copyright Business Wire 2008